To date, the only approved direct KRAS inhibitor is Sotorasib (AMG 510) which specifically targets KRAS p.Gly12Cys in non-small-cell lung carcinoma by forming a covalent bond with the 12-cysteine (18). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.